Published September 26, 2007 | Version v1
Journal article

Experimental iodine-125 seed irradiation of intracerebral brain tumors in nude mice

  • 1. Department of Radiation Oncology, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam (Netherlands)
  • 2. Department of Neurosurgery, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam (Netherlands)
  • 3. Department of Radiology, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam (Netherlands)
  • 4. Department of Cell Biology and Histology, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam (Netherlands)

Description

High-dose radiotherapy is standard treatment for patients with brain cancer. However, in preclinical research external beam radiotherapy is limited to heterotopic murine models– high-dose radiotherapy to the murine head is fatal due to radiation toxicity. Therefore, we developed a stereotactic brachytherapy mouse model for high-dose focal irradiation of experimental intracerebral (orthotopic) brain tumors. Twenty-one nude mice received a hollow guide-screw implanted in the skull. After three weeks, 5 × 105 U251-NG2 human glioblastoma cells were injected. Five days later, a 2 mCi iodine-125 brachytherapy seed was inserted through the guide-screw in 11 randomly selected mice; 10 mice received a sham seed. Mice were euthanized when severe neurological or physical symptoms occurred. The cumulative irradiation dose 5 mm below the active iodine-125 seeds was 23.0 Gy after 13 weeks (BEDtumor = 30.6 Gy). In the sham group, 9/10 animals (90%) showed signs of lethal tumor progression within 6 weeks. In the experimental group, 2/11 mice (18%) died of tumor progression within 13 weeks. Acute side effects in terms of weight loss or neurological symptoms were not observed in the irradiated animals. The intracerebral implantation of an iodine-125 brachytherapy seed through a stereotactic guide-screw in the skull of mice with implanted brain tumors resulted in a significantly prolonged survival, caused by high-dose irradiation of the brain tumor that is biologically comparable to high-dose fractionated radiotherapy– without fatal irradiation toxicity. This is an excellent mouse model for testing orthotopic brain tumor therapies in combination with radiation therapy

Availability note (English)

Available from http://dx.doi.org/10.1186/1748-717X-2-38; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2174502

Additional details

Publishing Information

Journal Title
Radiation Oncology (Online)
Journal Volume
2
Journal Page Range
p. 38
ISSN
1748-717X

Optional Information

Copyright
Copyright (c) 2007 Verhoeff et al
Notes
PMCID: PMC2174502; PUBLISHER-ID: 1748-717X-2-38; PMID: 17897452; OAI: oai:pubmedcentral.nih.gov:2174502; licensee BioMed Central Ltd.